MX381729B - Derivados espirodiamina como inhibidores de la aldosterona sintasa. - Google Patents

Derivados espirodiamina como inhibidores de la aldosterona sintasa.

Info

Publication number
MX381729B
MX381729B MX2017004541A MX2017004541A MX381729B MX 381729 B MX381729 B MX 381729B MX 2017004541 A MX2017004541 A MX 2017004541A MX 2017004541 A MX2017004541 A MX 2017004541A MX 381729 B MX381729 B MX 381729B
Authority
MX
Mexico
Prior art keywords
synthase inhibitors
aldosterone synthase
spirodiamine
derivatives
compounds
Prior art date
Application number
MX2017004541A
Other languages
English (en)
Other versions
MX2017004541A (es
Inventor
Alexander WAYWEG
Benoit Hornsperger
Bernd Kuhn
Dongbo Li
Hans Peter Maerki
Jianhua Yu
Johannes Aebi
Jun Wu
Junli Chen
Kurt E Amrein
Rainer E Martin
Xuefei Tan
Yongfu Liu
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54256743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX381729(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2017004541A publication Critical patent/MX2017004541A/es
Publication of MX381729B publication Critical patent/MX381729B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención proporciona nuevos compuestos que presentan la fórmula general (I): (ver Fórmula) en la que R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, A1, A2, m, n y p son tal como se indica en la presente descripción, composiciones que incluyen los compuestos y métodos de utilización de los compuestos.
MX2017004541A 2014-10-08 2015-10-05 Derivados espirodiamina como inhibidores de la aldosterona sintasa. MX381729B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2014088133 2014-10-08
PCT/EP2015/072887 WO2016055394A1 (en) 2014-10-08 2015-10-05 Spirodiamine derivatives as aldosterone synthase inhibitors

Publications (2)

Publication Number Publication Date
MX2017004541A MX2017004541A (es) 2017-06-27
MX381729B true MX381729B (es) 2025-03-13

Family

ID=54256743

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017004541A MX381729B (es) 2014-10-08 2015-10-05 Derivados espirodiamina como inhibidores de la aldosterona sintasa.

Country Status (21)

Country Link
US (1) US10035804B2 (es)
EP (1) EP3204383B1 (es)
JP (1) JP6613306B2 (es)
KR (1) KR102550852B1 (es)
CN (1) CN106852142B (es)
AU (1) AU2015330141B2 (es)
BR (1) BR112017006829B1 (es)
CA (1) CA2962122A1 (es)
CL (1) CL2017000804A1 (es)
CO (1) CO2017003132A2 (es)
CR (1) CR20170118A (es)
EA (1) EA035185B1 (es)
ES (1) ES2850198T3 (es)
IL (1) IL251106B (es)
MX (1) MX381729B (es)
PE (1) PE20171057A1 (es)
PH (1) PH12017500658B1 (es)
SG (1) SG11201702335VA (es)
UA (1) UA122061C2 (es)
WO (1) WO2016055394A1 (es)
ZA (1) ZA201701846B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI659021B (zh) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Kras g12c之抑制劑
LT3105218T (lt) 2014-02-13 2019-12-10 Incyte Corp Ciklopropilaminai kaip lsd1 inhibitoriai
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
WO2015123424A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
WO2016007731A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines and imidazopyrazines as lsd1 inhibitors
WO2016007736A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyrazines as lsd1 inhibitors
EA201792205A1 (ru) 2015-04-03 2018-02-28 Инсайт Корпорейшн Гетероциклические соединения как ингибиторы lsd1
DK3334709T3 (da) 2015-08-12 2025-02-03 Incyte Holdings Corp Salte af en lsd1-hæmmer
JP7327802B2 (ja) 2017-01-26 2023-08-16 アラクセス ファーマ エルエルシー 縮合ヘテロ-ヘテロ二環式化合物およびその使用方法
WO2018140599A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
US11136308B2 (en) 2017-01-26 2021-10-05 Araxes Pharma Llc Substituted quinazoline and quinazolinone compounds and methods of use thereof
EP3573954A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
EP3573971A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
JP7365237B2 (ja) 2017-03-21 2023-10-19 テンプル・ユニバーシティ-オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション シグマ-2受容体の新規調節物質およびその使用方法
AU2018249675B2 (en) 2017-04-06 2021-08-19 Inventiva New compounds inhibitors of the YAP/TAZ-TEAD interaction and their use in the treatment of malignant mesothelioma.
WO2018218069A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant kras, hras or nras
CN110869358A (zh) 2017-05-25 2020-03-06 亚瑞克西斯制药公司 Kras的共价抑制剂
BR112021001709A2 (pt) * 2018-08-01 2021-05-04 Araxes Pharma Llc compostos espiro heterocíclicos e métodos de uso dos mesmos para o tratamento de câncer
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
EP3632908A1 (en) 2018-10-02 2020-04-08 Inventiva Inhibitors of the yap/taz-tead interaction and their use in the treatment of cancer
AU2022260537A1 (en) * 2021-04-23 2023-09-21 F. Hoffmann-La Roche Ag Heterocyclic compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013033059A1 (en) * 2011-08-29 2013-03-07 Bristol-Myers Squibb Company Spiro bicyclic diamine derivatives as hiv attachment inhibitors
HRP20192323T1 (hr) * 2011-09-15 2020-03-20 F. Hoffmann - La Roche Ag Novi derivati dihidrokinolin-2-ona
US9073881B2 (en) * 2011-09-23 2015-07-07 Hoffmann-La Roche Inc. Benzoic acid derivatives
MX350717B (es) * 2011-11-30 2017-09-14 Hoffmann La Roche Nuevos derivados biciclicos de dihidroisoquinolin-1-ona.
RU2015137972A (ru) * 2013-03-08 2017-04-13 Ф. Хоффманн-Ля Рош Аг Новые производные дигидрохинолин-2-она в качестве ингибиторов альдостеронсинтазы (cyp1 1 b2 или cyp1 1 b1)
AR096423A1 (es) * 2013-05-27 2015-12-30 Hoffmann La Roche Compuestos de 3,4-dihidro-2h-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona
RU2693698C2 (ru) * 2013-05-27 2019-07-04 Ф. Хоффманн-Ля Рош Аг Новые соединения 3,4-дигидро-2н-изохинолин-1-она и 2,3-дигидроизоиндол-1-она
WO2014191338A1 (en) * 2013-05-27 2014-12-04 F. Hoffmann-La Roche Ag New 3,4-dihydro-2h-isoquinoline-1-one and 2,3-dihydro-isoindol-1-one compounds

Also Published As

Publication number Publication date
US10035804B2 (en) 2018-07-31
EP3204383B1 (en) 2020-11-18
ES2850198T3 (es) 2021-08-26
IL251106B (en) 2020-04-30
MX2017004541A (es) 2017-06-27
JP2017534606A (ja) 2017-11-24
JP6613306B2 (ja) 2019-11-27
KR102550852B1 (ko) 2023-07-05
PH12017500658A1 (en) 2017-10-02
US20170204107A1 (en) 2017-07-20
CN106852142A (zh) 2017-06-13
PH12017500658B1 (en) 2017-10-02
CR20170118A (es) 2017-07-10
CA2962122A1 (en) 2016-04-14
NZ729966A (en) 2024-02-23
PE20171057A1 (es) 2017-07-21
WO2016055394A1 (en) 2016-04-14
AU2015330141A1 (en) 2017-03-30
AU2015330141B2 (en) 2019-12-05
EA201790765A1 (ru) 2017-08-31
CN106852142B (zh) 2020-08-21
IL251106A0 (en) 2017-04-30
CL2017000804A1 (es) 2017-12-15
EA035185B1 (ru) 2020-05-12
BR112017006829B1 (pt) 2023-01-31
ZA201701846B (en) 2018-05-30
UA122061C2 (uk) 2020-09-10
BR112017006829A2 (pt) 2017-12-12
EP3204383A1 (en) 2017-08-16
KR20170057307A (ko) 2017-05-24
CO2017003132A2 (es) 2017-07-11
SG11201702335VA (en) 2017-04-27

Similar Documents

Publication Publication Date Title
PH12017500658A1 (en) Spirodiamine derivatives as aldosterone synthase inhibitors
PH12014501179A1 (en) New bicyclic dihydroisoquinoline-1-one derivatives
AU2015292632B2 (en) Aldosterone synthase inhibitors
EA201691594A1 (ru) Циклопропиламины в качестве ингибиторов lsd1
EA201891057A1 (ru) Композиции и способы для ингибирования активности аргиназы
UA117976C2 (uk) Сполуки амінопіримідинілу як інгібітори jak
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
UA117958C2 (uk) Похідні хіноксаліну, корисні як модулятори кінази fgfr
MX388591B (es) Derivados de pirazolopirimidina como inhibidor de cinasa.
MA39986A (fr) Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer
EA201692091A1 (ru) Хиноксалиновые соединения и их применение
EA201691481A1 (ru) ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
PH12016501462A1 (en) Neprilysin inhibitors
EA033264B1 (ru) Новый тритерпенон по с-3 с обратными амидными производными по с-17 в качестве ингибиторов вич
EA201890364A1 (ru) СОЕДИНЕНИЯ, ПРИГОДНЫЕ ДЛЯ ИНГИБИРОВАНИЯ ROR-ГАММА-t
EA201790156A1 (ru) Азетидинилоксифенилпирролидиновые соединения
EA201691796A1 (ru) П-замещенные асимметричные мочевины и их применение в медицине
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
EA201692518A2 (ru) Способы улучшения производительности миокарда у пациентов после операции фонтена с применением композиций уденафила
MX2016003926A (es) Nuevos derivados de fenil-dihidropiridina como inhibidores de aldosterona sintasa.
MX2016015298A (es) Inhibidores de nampt y metodos.
EA201650003A1 (ru) Соединённые циклоалкилом дигетероциклические производные
EA201790851A1 (ru) Способы предотвращения, уменьшения и лечения макулодистрофии
EA201700254A1 (ru) Комбинация